Find Fruquintinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1194506-26-7, Hmpl-013, Hmpl013, Fruquintinib [who-dd], Fruquintinib(hmpl-013), 6-(6,7-dimethoxyquinazolin-4-yl)oxy-n,2-dimethyl-1-benzofuran-3-carboxamide
Molecular Formula
C21H19N3O5
Molecular Weight
393.4  g/mol
InChI Key
BALLNEJQLSTPIO-UHFFFAOYSA-N
FDA UNII
49DXG3M5ZW

Fruquintinib
Fruquintinib is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, fruquintinib inhibits VEGF-induced phosphorylation of VEGFRs 1, 2, and 3 which may result in the inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and tumor cell death. Expression of VEGFRs may be upregulated in a variety of tumor cell types.
1 2D Structure

Fruquintinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
6-(6,7-dimethoxyquinazolin-4-yl)oxy-N,2-dimethyl-1-benzofuran-3-carboxamide
2.1.2 InChI
InChI=1S/C21H19N3O5/c1-11-19(20(25)22-2)13-6-5-12(7-16(13)28-11)29-21-14-8-17(26-3)18(27-4)9-15(14)23-10-24-21/h5-10H,1-4H3,(H,22,25)
2.1.3 InChI Key
BALLNEJQLSTPIO-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=C(C2=C(O1)C=C(C=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(=O)NC
2.2 Other Identifiers
2.2.1 UNII
49DXG3M5ZW
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Hmpl-013

2.3.2 Depositor-Supplied Synonyms

1. 1194506-26-7

2. Hmpl-013

3. Hmpl013

4. Fruquintinib [who-dd]

5. Fruquintinib(hmpl-013)

6. 6-(6,7-dimethoxyquinazolin-4-yl)oxy-n,2-dimethyl-1-benzofuran-3-carboxamide

7. Fruquintinib [usan]

8. 49dxg3m5zw

9. 6-(6,7-dimethoxyquinazolin-4-yloxy)-n,2-dimethylbenzofuran-3-carboxamide

10. 3-benzofurancarboxamide, 6-((6,7-dimethoxy-4-quinazolinyl)oxy)-n,2-dimethyl-

11. 6-[(6,7-dimethoxyquinazolin-4-yl)oxy]-n,2-dimethyl-1-benzofuran-3-carboxamide

12. 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-n,2-dimethylbenzofuran-3-carboxamide

13. Unii-49dxg3m5zw

14. Elunate

15. Fruquintinib [inn]

16. Fruquintinib; Hmpl-013

17. Fruquintinib (hmpl-013)

18. Schembl947183

19. Gtpl9428

20. Hmpl 013

21. Chembl4303214

22. Bcp15692

23. Ex-a2262

24. Nsc801000

25. Nsc829498

26. S5667

27. Who 10348

28. 6-[(6,7-dimethoxy-4-quinazolinyl)oxy]-n,2-dimethyl-3-benzofurancarboxamide

29. Akos026750586

30. Zinc114898570

31. Ccg-268573

32. Cs-5558

33. Db11679

34. Nsc-801000

35. Nsc-829498

36. Sb17123

37. Ncgc00481603-01

38. As-73141

39. Hmpl-013;hmpl013;hmpl 013

40. Hy-19912

41. B5864

42. A14393

43. C71641

44. A898991

45. Q27259271

46. B2693-470819

2.4 Create Date
2009-12-15
3 Chemical and Physical Properties
Molecular Weight 393.4 g/mol
Molecular Formula C21H19N3O5
XLogP33.4
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count7
Rotatable Bond Count5
Exact Mass393.13247072 g/mol
Monoisotopic Mass393.13247072 g/mol
Topological Polar Surface Area95.7 Ų
Heavy Atom Count29
Formal Charge0
Complexity579
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of colorectal carcinoma


Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty